We are a global clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types, with our multi-national R&D centers in both China and the United States. We have assembled a best-in-class management team, built our unique immuno-oncology platforms and partnered with multiple top pharmaceutical companies to promote innovation.

Leveraging collaborations and internal discoveries, we have identified seven drug candidates and developed a robust pipeline of product candidates. Currently, our pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as four preclinical candidates.